In this article, we will discuss about Pralsetinib (Dosage Overview). So, let’s get started.
Pralsetinib is indicated for the treatment of adult patients with metastatic RET fusion-positive
non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Select patients for treatment with Pralsetinib based on the presence of a RET gene fusion.
The recommended dosage of Pralsetinib is 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking Pralsetinib). Continue treatment until disease progression or until unacceptable toxicity.
If a dose of Pralsetinib is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for GAVRETO the next day. Do not take an additional dose if vomiting occurs after GAVRETO but continue with the next dose as scheduled